Keywords
pancreatic cancer
early detection
risk groups
How to Cite
Abstract
Introduction. Pancreatic cancer is characterized by one of the lowest rates of early detection among gastrointestinal tract tumors. In the early stages, the disease proceeds without pronounced clinical symptoms, and at the initial visit, more than half of patients are diagnosed with a locally advanced or metastatic stage of the disease. The development and application of new approaches to detecting pancreatic cancer at early stages is of great clinical importance.
Aim. Development and application of a method for the early detection of pancreatic cancer based on an organizational experiment in St. Petersburg and the Leningrad Region.
Materials and Methods. The organizational experiment involved a two-stage system for identifying and further testing patients identified as at risk for pancreatic cancer. During the first stage, patients at high risk for pancreatic cancer were identified in primary care facilities. During the second stage, targeted testing was conducted at the Federal Center to confirm the diagnosis, followed by analysis of the results.
Results. During the organizational experiment between January 2019 and December 2023, 2.162 patients were examined at the first stage, 735 of them were allocated to the risk group, of which the diagnosis was confirmed in 182 (24.7 %) patients. Stage 0 of the disease was registered in 22.5 %, stage I — in 35.1 %, stage II — in 33.5 %, III — 6.5 %). In 2.4 % of patients, distant metastases were detected during examination notable that in these case size of the primary lesion in the pancreas did not exceed 2 cm.
Conclusion. The conducted organizational experiment demonstrated the effectiveness of the proposed method of early detection of pancreatic cancer both at the stage of primary health care and in a specialized center.
References
Zottl J., Sebesta C.G., Tomosel E., et al. Unraveling the burden of pancreatic cancer in the 21st century: Trends in incidence, mortality, survival, and key contributing factors. Cancers (Basel). 2025; 17(10): 1607.-DOI: https://doi.org/10.3390/cancers17101607.
Siegel R.L., Kratzer T.B., Giaquinto A.N., et al. Cancer statistics, 2025. CA Cancer J Clin. 2025; 75(1): 10-45.-URL: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21871.
Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.-URL: https://pubmed.ncbi.nlm.nih.gov/33538338.
Cipora E., Partyka O., Pajewska M., et al. Treatment costs and social burden of pancreatic cancer. Cancers (Basel). 2023; 15(6): 1911.-DOI: https://doi.org/10.3390/cancers15061911.
Кудашкин Н.Е., Гладков О.А., Загайнов В.Е., et al. Рак поджелудочной железы. Клинические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли. 2025; 15(3s2): 464–479.-DOI: https://doi.org/10.18027/2224-5057-2025-15-3s2-1.1-18 [Kudashkin N.E., Gladkov O.A., Zagaynov V.E., et al. Pancreatic cancer. Malignant Tumours. 2025; 15(3s2-1.1): 464–479.-DOI: https://doi.org/10.18027/2224-5057-2025-15-3s2-1.1-18 (In Rus)].
Clift A.K., Tan P.S., Patone M., et al. Predicting the risk of pancreatic cancer in adults with new-onset diabetes: development and internal-external validation of a clinical risk prediction model. Br J Cancer. 2024; 130(12), 1969–1978.-DOI: https://doi.org/10.1038/s41416-024-02693-9.
Kawai M., Fukuda A., Otomo R., et al. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Br J Cancer. 2024; 131: 1158–1168.-URL: https://pubmed.ncbi.nlm.nih.gov/39198617/.
Lin Z., Adeniran E.A., Cai Y., et al. Early detection of pancreatic cancer: current advances and future opportunities. Biomedicines 2025; 13, 1733.-DOI: https://doi.org/10.3390/biomedicines13071733.
Hernández-Blanquisett A., Quintero-Carreño V., Martínez-Ávila M.C., et al. Metastatic pancreatic cancer: Where are we? Oncol Rev. 2024; 17: 11364.-URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10830814/.-DOI: https://doi.org/10.3389/or.2023.11364.
Osei-Bordom D.C., Serifis N., Brown Z.J., et al. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. Surg Oncol. 2022; 43: 101803.-DOI: https://doi.org/10.1016/j.suronc.2022.101803.
Yamada R., Tsuboi J., Murashima Y., et al. Advances in the early diagnosis of pancreatic ductal adenocarcinoma and premalignant pancreatic lesions. Biomedicines. 2023; 11(6): 1687.-DOI: https://doi.org/10.3390/biomedicines11061687.
Montoya Mira J.L., Quentel A., Patel R.K.,et al. Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay. Sci Transl Med. 2025; 17(785).-DOI: https://doi.org/10.1126/scitranslmed.adq3110.
Hajibandeh S., Intrator C., Carrington-Windo E., et al. Accuracy of the END-PAC model in predicting the risk of developing pancreatic cancer in patients with new-onset diabetes: A systematic review and meta-analysis. Biomedicines. 2023; 11(11): 3040.-DOI: https://doi.org/10.3390/biomedicines11113040.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 владислав, Кочорова Лариса Валерьяновна, Павловский Александр Васильевич, Попов Сергей Александрович, Стаценко Андрей Анатольевич, Вишняков Николай Иванович, Прядко Андрей Станиславович, Алексеев Сергей Михайлович, Ширшова Наталья Юрьевна, Гранов Дмитрий Анатольевич